Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADAG Adagene	$2.18 -8.0%	$1.98	$1.33 ▼ $3.58	$102.70M	0.74	69,561 shs	55,485 shs
COYA Coya Therapeutics	$6.56 -2.5%	$6.08	$4.65 ▼ $10.24	$109.72M	0.26	76,142 shs	67,029 shs
EQ Equillium	$1.94 -0.5%	$0.62	$0.27 ▼ $2.26	$115.43M	1.15	3.49 million shs	1.54 million shs
RNTX Rein Therapeutics	$1.12 -3.0%	$1.35	$1.04 ▼ $4.40	$25.99M	1.31	50,879 shs	48,394 shs

Beginner's Guide To Retirement Stocks

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADAG Adagene	+0.85%	+20.92%	+19.10%	+28.11%	-21.00%
COYA Coya Therapeutics	+3.54%	+13.30%	+0.90%	+20.18%	+10.87%
EQ Equillium	+2.63%	+62.50%	+384.23%	+419.17%	+73.33%
RNTX Rein Therapeutics	-2.54%	+4.55%	-21.23%	-41.33%	+114,999,900.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ADAG Adagene	3.0024 of 5 stars	3.5	5.0	0.0	0.0	2.7	1.7	0.0
COYA Coya Therapeutics	1.7946 of 5 stars	3.5	2.0	0.0	0.0	2.5	0.8	0.0
EQ Equillium	1.0844 of 5 stars	1.0	5.0	0.0	0.0	3.2	1.7	0.0
RNTX Rein Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADAG Adagene	3.00	Buy	$7.00	221.10% Upside
COYA Coya Therapeutics	3.00	Buy	$16.50	151.52% Upside
EQ Equillium	2.00	Hold	$1.00	-48.45% Downside
RNTX Rein Therapeutics	2.00	Hold	N/A	N/A

Current Analyst Ratings Breakdown

Latest RNTX, COYA, EQ, and ADAG Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/25/2025	COYA Coya Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$18.00
8/25/2025	COYA Coya Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$18.00
8/19/2025	RNTX Rein Therapeutics	Brookline Capital Management Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold
8/15/2025	ADAG Adagene	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$8.00 ➝ $7.00
8/13/2025	COYA Coya Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$18.00
8/13/2025	COYA Coya Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$14.00
8/6/2025	ADAG Adagene	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
8/6/2025	ADAG Adagene	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$7.00
7/24/2025	COYA Coya Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$18.00
7/9/2025	COYA Coya Therapeutics	Lake Street Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$16.00
7/1/2025	COYA Coya Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$14.00

(Data available from 8/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADAG Adagene	$100K	1,027.00	N/A	N/A	$0.80 per share	2.73
COYA Coya Therapeutics	$423.45K	259.10	N/A	N/A	$1.69 per share	3.88
EQ Equillium	$41.10M	2.81	N/A	N/A	$0.08 per share	24.25
RNTX Rein Therapeutics	N/A	N/A	$0.42 per share	2.64	$0.13 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADAG Adagene	-$33.42M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	N/A
COYA Coya Therapeutics	-$14.88M	-$1.24	N/A	N/A	N/A	N/A	-61.05%	-53.61%	11/5/2025 (Estimated)
EQ Equillium	-$8.07M	-$0.56	N/A	N/A	N/A	-19.62%	-139.56%	-90.56%	11/12/2025 (Estimated)
RNTX Rein Therapeutics	-$62.88M	-$2.69	N/A	N/A	N/A	N/A	-141.11%	-33.83%	N/A

Latest RNTX, COYA, EQ, and ADAG Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	EQ Equillium	-$0.14	-$0.16	-$0.02	-$0.16	N/A	N/A
8/14/2025	Q2 2025	RNTX Rein Therapeutics	-$0.22	-$0.28	-$0.06	-$0.28	N/A	N/A
8/12/2025	Q2 2025	COYA Coya Therapeutics	-$0.22	-$0.36	-$0.14	-$0.36	$0.78 million	$0.16 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADAG Adagene	N/A	N/A	N/A	N/A	N/A
COYA Coya Therapeutics	N/A	N/A	N/A	N/A	N/A
EQ Equillium	N/A	N/A	N/A	N/A	N/A
RNTX Rein Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADAG Adagene	0.01	2.29	2.30
COYA Coya Therapeutics	N/A	7.43	7.43
EQ Equillium	N/A	1.65	1.65
RNTX Rein Therapeutics	N/A	0.86	0.86

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADAG Adagene	9.51%
COYA Coya Therapeutics	39.75%
EQ Equillium	27.05%
RNTX Rein Therapeutics	90.89%

Insider Ownership

Company	Insider Ownership
ADAG Adagene	21.20%
COYA Coya Therapeutics	12.00%
EQ Equillium	30.30%
RNTX Rein Therapeutics	5.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADAG Adagene	260	47.11 million	37.12 million	Not Optionable
COYA Coya Therapeutics	6	16.73 million	14.72 million	Not Optionable
EQ Equillium	40	59.50 million	41.47 million	Not Optionable
RNTX Rein Therapeutics	9	23.31 million	22.12 million	N/A

RNTX, COYA, EQ, and ADAG Headlines

Recent News About These Companies

Rein Therapeutics (NASDAQ:RNTX) Cut to "Hold" at Brookline Capital Management

August 21, 2025 | americanbankingnews.com

Brookline Capital Downgrades Rein Therapeutics (RNTX)

August 19, 2025 | msn.com

Rein announces U.K. MHRA authorized to initiate Phase 2 ‘RENEW’ trial

August 19, 2025 | msn.com

Rein Therapeutics Wins U.K. Approval to Launch Phase 2 Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis

August 19, 2025 | globenewswire.com

Rein Therapeutics to Present Novel IPF Science and Clinical Development Insights at IPF Summit 2025

August 14, 2025 | globenewswire.com

XtalPi and DoveTree Announce Landmark $6 Billion AI Drug Discovery Collaboration

August 7, 2025 | finance.yahoo.com

Rein Therapeutics Enters into Agreements for up to $21 Million in Flexible Financing

July 30, 2025 | finance.yahoo.com

RNTX - Rein Therapeutics Inc Dividends - Morningstar

June 26, 2025 | morningstar.comM

Rein Therapeutics Announces Adjournment of Annual Meeting of Stockholders

June 24, 2025 | prnewswire.com

US FDA puts on hold Rein Therapeutics' lung disease drug trial

June 12, 2025 | reuters.com

RNTX Rein Therapeutics Inc.

June 1, 2025 | seekingalpha.com

Rein Therapeutics, Inc.: Rein Therapeutics Announces First Patient Dosed in RENEW Phase 2 Trial of LTI-03 in Patients with IPF

May 27, 2025 | finanznachrichten.de

Rein Therapeutics Announces First Patient Dosed in RENEW Phase 2 Trial of LTI-03 in Patients with IPF

May 27, 2025 | prnewswire.com

Rein Therapeutics Presents Two Posters at the American Thoracic Society 2025 International Conference

May 19, 2025 | prnewswire.com

Rein Therapeutics, Inc.: Rein Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

May 16, 2025 | finanznachrichten.de

Rein Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

May 15, 2025 | prnewswire.com

Rein Therapeutics begins trial for idiopathic pulmonary fibrosis treatment

May 13, 2025 | msn.com

Rein Therapeutics, Inc.: Rein Therapeutics Announces Initiation of RENEW Phase 2 Trial of LTI-03 in Patients with IPF

May 12, 2025 | finanznachrichten.de

Rein Therapeutics Announces Initiation of RENEW Phase 2 Trial of LTI-03 in Patients with IPF

May 12, 2025 | prnewswire.com

Rein Therapeutics to integrate Qureight’s platform in trial of IPF treatment

May 2, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

RNTX, COYA, EQ, and ADAG Company Descriptions

Adagene NASDAQ:ADAG

$2.18 -0.19 (-8.02%)

Closing price 03:58 PM Eastern

Extended Trading

$2.19 +0.01 (+0.46%)

As of 04:04 PM Eastern

Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti- CD137 IgG4 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a masked fully-human anti-CTLA-4 mAb that is in Phase 1 clinical trial for the treatment advanced/metastatic solid tumors; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase 1b/2 clinical development for the treatment of advanced/metastatic solid tumors. It also offers ADG104, an anti-PD-L1 mAb that is in Phase 2 clinical development; ADG125, a novel anti-CSF-1R mAb, which is in Phase I clinical trial; ADG206, a masked, Fc engineered anti-CD137 agonistic POWERbody; ADG153, a masked anti-CD47 IgG1 SAFEbody, which is in preclinical for the treatment hematologic and solid tumors; ADG138, novel HER2xCD3 POWERbody, which is in preclinical for the treatment HER2-expressing solid tumors; and ADG152, a v POWERbody, which is in preclinical stage for the treatment off-tumor toxicities, as well as develops anti-CD28 bispecific POWERbody TCEs. The company was incorporated in 2011 and is headquartered in Suzhou, China.

Coya Therapeutics NASDAQ:COYA

$6.56 -0.17 (-2.53%)

Closing price 03:58 PM Eastern

Extended Trading

$6.56 0.00 (0.00%)

As of 04:04 PM Eastern

Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. It is developing COYA 101, an autologous regulatory T-cell product candidate that has completed Phase 2a clinical trial for use in the treatment of Amyotrophic Lateral Sclerosis. The company's product candidates in IND-enabling studies include COYA 301, a low-dose interleukin 2 Treg-enhancing biologic, which is in Phase 2 clinical trial for use in the treatment of Frontotemporal Dementia; and COYA 302, a biologic combination for subcutaneous administration intended to enhance Treg function while depleting T effector function and activated macrophages for use in the treatment of neurodegenerative and autoimmune diseases. It is also developing COYA 201, an antigen directed Treg-derived exosome product candidate that is in preclinical stage for use in the treatment of neurodegenerative, autoimmune, and metabolic diseases; and COYA 206, an antigen directed Treg-derived exosome product candidate, which is in discovery stage. The company has a collaboration with Dr. Reddy's Laboratories SA for the development and commercialization of COYA 302, an investigational combination therapy for treatment of amyotrophic lateral sclerosis. The company was incorporated in 2020 and is headquartered in Houston, Texas.

Equillium NASDAQ:EQ

$1.94 -0.01 (-0.51%)

Closing price 03:59 PM Eastern

Extended Trading

$1.84 -0.10 (-5.15%)

As of 04:08 PM Eastern

Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a first-in-class monoclonal antibody that targets the immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase I clinical trial for the treatment of ulcerative colitis; and Phase I clinical trial for the treatment of lupus nephritis. It also develops EQ101 completed phase 1/2 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ302 to treat gastrointestinal indications. In addition, it serves dermatology, gastroenterology, rheumatology, hematology, transplant science, oncology, and pulmonology area. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.

Rein Therapeutics NASDAQ:RNTX

$1.12 -0.04 (-3.04%)

As of 03:50 PM Eastern

Rein Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of a novel class of therapeutics for the treatment of cancer and other diseases. It focuses on its lead product candidate, ALRN-6924, which is a cell-permeating peptide that disrupts the interaction of p53 suppressors MDM2 and MDMX with tumor suppressor p53 to reactivate tumor suppression in non-mutant, or wild-type, p53 cancers. The company was founded by Gregory L. Verdine, Rosana Kapeller, Huw M. Nash, Joseph A. Yanchik III, and Loren David Walensky on August 6, 2001 and is headquartered in Austin, TX.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time